Advanced chemorefractory epithelial thymic tumors are still a challenge in clinical oncology. A therapeutic approach targeting a key molecular pathway could be the ideal solution in a neoplasm that can overexpress epidermal growth factor receptor (EGFR) in the epithelial component.
Methods
A patient with metastatic heavily pretreated thymic carcinoma was evaluated for EGFR expression in the primary tumor.
Results
Strong EGFR expression was revealed by immunohistochemistry. The patient received erlotinib therapy but had obtained no response after four months of treatment.
Conclusion
This preliminary experience suggests that erlotinib may not be a useful therapeutic choice in advanced pretreated thymic carcinomas.
AzarowK.S., PearlR.H., ZurcherR., EdwardsF.H., CohenA.J.: Primary mediastinal masses: a comparison of adult and pediatric populations.J Thorac Cardiovasc Surg Cancer, 106: 67–72, 1993.
2.
PapapopoulosK.P., ThomasC.R.: Current chemotherapy options for thymic epithelial neoplasm.Expert Opin Pharmacother, 6: 1169–1177, 2005.
3.
FontaniniG., VignatiS., BiginiD., MussiA., LucchiH., AngelettiC.A., PingitoreR., PepeS., BasoloF., BevilacquaG.: Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype.Eur J Cancer, 31: 178–183, 1995.
4.
IssingW.J., LiebichC., WustrowT.P., UllrichA.: Coexpression of epidermal growth factor receptor and TGF-alpha and survival in upper aerodigestive tract cancer.Anticancer Res, 16: 283–288, 1996.
5.
XiaW., BisiJ., StrumJ., LiuL., CarrickK., GrahamK.M., TreeceA.L., HardwickeM.A., DushM., LiaoQ., WestlundR.E., ZhaoS., BacusS., SpectorN.L.: Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.Cancer Res, 66: 1640–1647, 2006.
6.
HenleyJ.D., CummingsO.W., LoehrerP.J.: Tyrosine kinase receptor expression in thymomas.J Cancer Res Clin Oncol, 130: 222–224, 2004.
7.
HenleyJ.D., KoukoulisG.K., LoehrerP.J.: Epidermal growth factor receptor expression in invasive thymoma.J Cancer Res Clin Oncol, 128: 167–170, 2002.
8.
HayashiY., IshiiN., ObayashiC., JinnaiK., HaniokaK., ImaiY., ItohH.: Thymoma: tumour type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erb B and ras p21.Virchows Arch, 426: 43–50, 1995.
9.
ShepherdF.A., Rodrigues PereiraJ., CiuleanuT., TanE.H., HirshV., ThongprasertS., CamposD., MaoleekoonpirojS., SmylieM., MartinsR., van KootenM., DediuM., FindlayB., TuD., JohnstonD., BezjakA., ClarkG., SantabarbaraP., SeymourL.: Erlotinib in previously treated non small cell lung cancer.N Engl J Med, 353: 123–133, 2005.
10.
UmemuraS., SegawaY., FujiwaraK., TakataI., SekiN., TokudaY., EguchiK., MandaiK.: A case of recurrent metastatic thymoma showing a marked response to paclitaxel monotherapy.Jpn J Clin Oncol, 32: 262–265, 2002.
11.
TakamizawaA., KoizumiT., KuboK., SekiguchiM., HondaT.: A case of relapsed thymic carcinoma that responded remarkably to chemotherapy with CPT-11.Gan To Kagaku Ryoho, 25: 2115–2118, 1998.
12.
LoehrerPJSr, WangW., JohnsonD.H., AisnerS.C., EttingerD.S.: Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group phase II trial.J Clin Oncol, 22: 293–299, 2004.
13.
PalmieriG., MarinoM., SalvatoreM., BudillonA., MaoG., CaragliaM., MontellaL.: Cetuximab is an active treatment of metastatic and chemorefractory thymoma.Front Biosci, 12: 757–761, 2007.
14.
KurupA., BurnsM., Drop choS., PaoW., LoehrerP.J.: Phase II study of gefinitib treatment in advanced thymic malignancies.J Clin Oncol (ASCO Annual Meeting Proc), 23 (suppl 16): 7068(abstr), 2005.
15.
FarinaG., GarassinoM.C., GambacortaM., La VerdeN., GherardiG., ScanniA.: Response of thymoma to cetuximab.Lancet Oncol, 8: 449–450, 2007.
16.
CunninghamD., HumbletY., SienaS., KhayatD., BleibergH., SantoroA., BetsD., MueserM., HarstrickA., VerslypeC., ChauI., Van CutsemE.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.N Engl J Med, 351: 337–345, 2004.
17.
HechtJ.R., PatnaikA., MalikI., VenookA., BerlinJ., CroghanG., WiensB.L., VisonneauS., JerianS., MeropolN.J.: ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis.J Clin Oncol (ASCO Annual Meeting Proc), 22 (suppl 14): 3511(abstr), 2004.
18.
TsaoM.S., SakuradaA., LorimerI., CutzJ., Kamel-ReidS., SquireJ., DingK., FrankR., SeymourL., ShepherdF.: Molecular analysis of the epidermal growth factor receptor (EGFR) gene and protein expression in patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial BR.21.J Clin Oncol (ASCO Annual Meeting Proc), 23 (suppl 16): 7007(abstr), 2005.
19.
ScartozziM., BearziI., BerardiR., MandolesiA., FabrisG., CascinuS.: Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.J Clin Oncol, 22: 4772–4778, 2004.
20.
GillG.N., BerticsP.J., SantonJ.B.: Epidermal growth factor and its receptor.Mol Cell Endocrinol, 51: 169–186, 1987.
